Activotec, a supplier of innovative products, consumables and services for peptide and protein synthesis, has reported 20% growth in sales for the financial period ending 31st December 2006
Benefiting from several new product introductions, increased international sales / marketing activity and significant interest in the company's proprietary peptide backbone modification technologies to develop GLP-1 analogues (for diabetes therapeutics), the company continued its strong worldwide growth.
Notable successes for the company included strong sales of custom peptides and proteins as well as extremely positive customer feedback to the PLS organic synthesiser and the Activo-P11 peptide synthesiser.
The PLS organic synthesiser is an easy-to-use and affordable instrument for parallel solution and solid phase chemistry.
Simple to set-up, and accommodating a wide range of glass reactors, the PLS organic synthesiser can perform up to 24 reactions simultaneously.
Designed by chemists for chemists, the new fully automated Activo-P11 peptide synthesiser is very easy to use.
Combining compatibility with a wide range of commercially available resins and reagents with the ability to perform a wide range of Fmoc and t-Boc chemistries the versatile Activo-P11 is able to synthesise peptides of almost any length in the 0.1-1.0mmol scale.
Chris Littlewood, managing director/CEO of Activotec, commented: "Beyond the exciting new products and innovations in peptide and protein synthesis our success in 2006 was contributed to by our drive to provide top quality informed support and maintaining high product quality.
"With continuing investment in innovative research, new products and customer facing staff we are aiming for high double-digit growth again in 2007".
Activotec has an extensive ongoing R+D programme targeted at developing novel methods for the modification and production of peptides and proteins for therapeutic use.
